Search
Now showing items 1-2 of 2
CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.
(2016-07)
Patnaik and colleagues report on the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of abemaciclib for the treatment of advanced solid cancers, demonstrating antitumor activity in advanced breast ...
Immuno-oncology combinations: raising the tail of the survival curve.
(2016-06)
There have been exponential gains in immuno-oncology in recent times through the development of immune checkpoint inhibitors. Already approved by the U.S. Food and Drug Administration for advanced melanoma and non-small ...